In 2015, the single interministerial fund (FUI) approved the TYROMAB (TYROsine kinase receptor Monoclonal AntiBody) project, led by a consortium of two Rhône alpine industrial stakeholders, ElsaLys Biotech, consortium leader, and PX'Therapeutics, the Aguettant pharmaceuticals group’s bioproduction subsidiary – as well as a world-renowned cancer care and research center, Centre Léon Bérard (CLB), based in Lyon.
Innovative in terms of its form and substance, TYROMAB provided a response to a twofold public health challenge: speeding up the development of new therapeutic antibodies against cancers and reducing their price, which notably entails decreasing their production cost.
The Auvergne-Rhône-Alpes region supported ElsaLys Biotech when it set up its research unit in Lyon at the end of 2016.
This support from the Auvergne Rhône Alpes Region to ElsaLys Biotech is an illustration of the Region's involvement in industry, particularly in supporting young innovative structures, and, in general, its investment in improvement of the quality of life of the population at the local level, but also at national and international level, providing new medical treatments.
